What records are connected here?
- Evidence lanes
- 3
- Source years
- 7
- Drugs@FDA applications
- 2
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsSkin
Difelikefalin is a synthetic peptide that activates kappa opioid receptors, and is the active ingredient in Korsuva.1,2 FDA approved Korsuva in 2021 for moderate-to-severe itching caused by chronic kidney disease in adults on hemodialysis.1,2 In two randomized, placebo-controlled trials of 851 adults, more people on difelikefalin had a meaningful drop in itch scores at 12 weeks. The label warns about dizziness, sleepiness and confusion.1
| What it is | A synthetic peptide kappa opioid receptor agonist. The label states that the relevance of kappa receptor activation to its effect is not known.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Korsuva with an original approval date of August 23, 2021. The cited label has no boxed warning.1,2 |
| Human evidence | Two randomized, double-blind, placebo-controlled 12-week trials in 851 adults on hemodialysis with moderate-to-severe itching, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Difelikefalin is a synthetic peptide that the label describes as a kappa opioid receptor agonist.1
In the United States it is the active ingredient of Korsuva, approved under NDA 214916, according to Drugs@FDA.2
It activates the kappa opioid receptor. The label states that the relevance of this activation to its effect on itching is not known.1
The label describes two randomized, multicenter, double-blind, placebo-controlled trials that enrolled 851 adults on hemodialysis with moderate-to-severe itching, treated for 12 weeks.1
The main outcome was an improvement of at least 4 points on a 0-to-10 worst-itch scale. It was reached by 40% on difelikefalin versus 21% on placebo in Trial 1, and 37% versus 26% in Trial 2, according to the label.1
The label reports that dizziness, sleepiness, changes in mental status and unsteady walking, including falls, have occurred in patients taking it.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Korsuva, application NDA 214916, with an original approval date of August 23, 2021.2
The Korsuva label cited here (DailyMed SPL version 9, published September 1, 2025) states that it is indicated for moderate-to-severe itching associated with chronic kidney disease in adults undergoing hemodialysis, and that it has not been studied in people on peritoneal dialysis.1
The label has no boxed warning and lists no contraindications. Its warnings cover dizziness, sleepiness, mental status changes and gait problems, and impaired ability to drive or operate machinery.1
How kappa receptor activation relieves itching, which the label states is not known.1
Its effect in people on peritoneal dialysis, in whom the label states it has not been studied.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Difelikefalin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Difelikefalin are a bounded selection, not every registration or paper about Difelikefalin. For the years before Difelikefalin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Difelikefalin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Difelikefalin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Korsuva for kidney-disease itching in adults on hemodialysis. Two randomized, placebo-controlled trials of 851 adults described in the label found more meaningful itch improvement with difelikefalin. The label warns about dizziness, sleepiness and mental status changes.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Korsuva for kidney-disease itching in adults on hemodialysis. Two randomized, placebo-controlled trials of 851 adults described in the label found more meaningful itch improvement with difelikefalin. The label warns about dizziness, sleepiness and mental status changes.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
New Drugs Update: Finerenone, Difelikefalin, and Avacopan.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
New Drugs Update: Finerenone, Difelikefalin, and Avacopan.↗Source date November 9, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT06593392↗Source date October 23, 2026Regulatory · added November 15, 2026
Drugs@FDA application ANDA220919↗Source date August 31, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
6 of 6 selected trial records include at least one phase value; 6 of 6 include a status value in the retained structured contract.
14 of 14 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT03422653 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin.
PeptideScanner retained ClinicalTrials.gov record NCT03617536 at 2026-11-15T21:56:33.343Z. Its registry update date was 2024-01-24, and PeptideScanner's reviewed identity mapping was difelikefalin.
PeptideScanner retained ClinicalTrials.gov record NCT03636269 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin.
14 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span January 27, 2020 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 35337427 in The Senior care pharmacist as Journal Article, with publication-date metadata of 2022-04-01 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06593392 at 2026-11-15T21:56:33.343Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was difelikefalin.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 220919 with status AP dated 2026-08-31, and names difelikefalin acetate among the application record's active ingredients.↗
Literature metadata
PubMed lists PMID 38253036 in American journal of nephrology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 31702883 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2019-11-08 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 36780675 in The New England journal of medicine as Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-09 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39037824 in Kidney360 as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-22 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38320524 in NEJM evidence as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39712488 in Frontiers in pharmacology as Journal Article, Systematic Review, with publication-date metadata of 2024-12-06 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03617536 at 2026-11-15T21:56:33.343Z. Its registry update date was 2024-01-24, and PeptideScanner's reviewed identity mapping was difelikefalin.↗
Regulatory
The Federal Register published notice 2023-26106, attributed to FDA and its parent HHS department, on 2023-11-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.↗
Literature metadata
PubMed lists PMID 32433845 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026